Biological Effects of Quercetin in COPD

Description

This study determines whether quercetin supplementation reduces the inflammation and oxidative stress markers in patients with chronic obstructive pulmonary disease. It is small study with 8 subjects receive quercetin 2000 mg/day and 4 subjects receive placebo.

Conditions

Chronic Obstructive Pulmonary Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

This study determines whether quercetin supplementation reduces the inflammation and oxidative stress markers in patients with chronic obstructive pulmonary disease. It is small study with 8 subjects receive quercetin 2000 mg/day and 4 subjects receive placebo.

Impact of Quercetin on Inflammatory and Oxidative Stress Markers in COPD

Biological Effects of Quercetin in COPD

Condition
Chronic Obstructive Pulmonary Disease
Intervention / Treatment

-

Contacts and Locations

Philadelphia

Nathaniel Marchetti, Philadelphia, Pennsylvania, United States, 19140

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Subjects with COPD, 40 - 80 yrs of age
  • * Post-bronchodilator forced expiratory volume (FEV)1/forced vital capacity (FVC) ratio 0.7, FEV1% predicted between 40 to 70
  • * Both active and ex-smokers with at least 10 pack-years history of smoking
  • * COPD patients taking H2 antagonists, loperamide or loratadine and willing to stop during the study period
  • * Known allergy/sensitivity to quercetin
  • * Subjects with primary current diagnosis of asthma
  • * Upper respiratory tract infection within two weeks of the screening visit
  • * Acute bacterial infection requiring antibiotics within two weeks of screening
  • * Emergency treatment or hospitalization within one month of screening for any reasons
  • * Unwillingness to stop flavonoid supplementation
  • * Dietary intake exceeding or averaging 150 mg quercetin daily as assessed by Bioflavonoid Food and Supplement Screener
  • * Daily warfarin or cyclosporine (Neoral, Sandimmune)
  • * Subjects taking H2 antagonists (cimetidine, ranitidine), loperamide (Imodium) or loratadine and not willing to stop during study period
  • * Lung cancer history or undergoing chemo- or radiation therapy
  • * Inflammatory bowel disease
  • * Subjects with no detectable levels of inflammatory CRP or SP-D in blood and/or IL-
  • * Women of child-bearing age and unwilling to take pregnancy test
  • * Child-bearing age, who are unwilling to use adequate contraception or abstain during the course of the study.
  • * Pregnant or lactating mothers

Ages Eligible for Study

40 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Temple University,

Nathaniel Marchetti, D.O., PRINCIPAL_INVESTIGATOR, Temple University

Study Record Dates

2025-07-01